Compare Abeona Therapeutics Inc (ABEO) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Medpace Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Medpace Holdings Inc trades at $529.18 (market cap $15.60B). The key difference: Medpace Holdings Inc is far larger — about 41.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | MEDP | |
|---|---|---|
Market Cap | $373.32M | $15.60B |
Sector | Health | Technology |
52-Week High | $7.23 | $620.59 |
52-Week Low | $4.17 | $308.88 |
Enterprise Value | $228.22M | $15.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Medpace (MEDP) trades at $565.09, up 1.34% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, 17.19% net margins, and robust ROE of 77.25%. Recent news highlights shifting CRO demand dynamics and upcoming Q2 2026 earnings on July 22. The stock trades near 52-week highs with technical indicators showing overbought conditions.
MEDP presents growth potential from steady revenue expansion and strong profitability, though elevated valuations (P/E 35.59) and class action lawsuits pose risks. Analyst consensus leans cautious with 63% hold ratings and $465 price target below current levels. The stock's upside depends on continued earnings outperformance and backlog quality improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
